Angiocrine Bioscience
Angiocrine is a San Diego company that infuses engineered blood-vessel lining cells to help patients recover from the high-dose chemotherapy given before stem cell transplants for lymphoma and myeloma.
Overview
Angiocrine Bioscience, founded in 2012 in San Diego from Weill Cornell research, develops AB-205, an engineered endothelial cell product given after high-dose chemotherapy and autologous stem cell transplant to reduce severe regimen-related toxicities such as mucositis. It leads a phase 3 trial in lymphoma patients registered on ClinicalTrials.gov.
Similar pages
not linked directly; found by shared links- CompanyChongqing Precision Biotech
Shares Pivotal (registrational) trial, Clinical trial, Multiple myeloma and the tag ctgov-sponsor.
- CompanyAeterna Zentaris
Shares Pivotal (registrational) trial, Clinical trial, Multiple myeloma and the tag ctgov-sponsor.
- CompanyActive Biotech
Shares Pivotal (registrational) trial, Clinical trial, Multiple myeloma and the tag ctgov-sponsor.
- CompanyDenovo Biopharma
Shares Pivotal (registrational) trial, Clinical trial, Diffuse large B-cell lymphoma and the tag ctgov-sponsor.
- CompanyCartesian Therapeutics
Shares Pivotal (registrational) trial, Clinical trial, Multiple myeloma and the tag ctgov-sponsor.
- CompanyCSL Limited
Shares Pivotal (registrational) trial, Clinical trial and the tag ctgov-sponsor.
- CompanyD3 Bio (Wuxi)
Shares Pivotal (registrational) trial, Clinical trial and the tag ctgov-sponsor.
- CompanyDong-A ST
Shares Pivotal (registrational) trial, Clinical trial and the tag ctgov-sponsor.